#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow

Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067

Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts. POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV

• https://x.com/bella_mehta/status/2062861627444404540/photo/1

#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5

• https://x.com/Yuz6Yusof/status/2062849640374890515/photo/1

Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA? Yes: faster remission at week 4 (84.6% vs 15%) But: equal at week 24 Prospective study in 46 patients #POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0

• https://x.com/Nellziade/status/2062849233623908374/photo/1

Top tips: ⭐️ Summarise the key facts but always provide the source ⭐️ Learn from mistakes to improve what you have ⭐️ Have high quality source material- scan multiple resources for the best quality info and latest news! @RheumNow #EULAR2026

What makes a good rheum learning platform? @rheumnow’s Dr Jack Cush gives a masterclass in online learning and medical education, including the background to RheumNow. #EULAR2026 @EMEUNET https://t.co/2cXpRXPK13

• https://x.com/DrMiniDey/status/2062847194902720581/photo/1
• https://x.com/DrMiniDey/status/2062847194902720581/photo/1

What do you think about this cartoon-style format for posters? A- I love it! B- It’s Ok but I prefer classic As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients #POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi

• https://x.com/Nellziade/status/2062847138959081686/photo/1

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit

• https://x.com/Yuz6Yusof/status/2062846673345233231/photo/1

OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB

• https://x.com/KDAO2011/status/2062845784001798348/photo/1

Which imaging test has the highest carbon footprint??? Think wisely before prescribing 🩻 #EULAR2026 @RheumNow https://t.co/36Ej8smWRd

• https://x.com/Nellziade/status/2062844472522666061/photo/1

Did you take part in #RheumaVision this year? @cristianasieiro takes us through the past, present & future of this innovative initiative, which held its final yesterday at #EULAR2026. You can watch all the videos online- and be sure to participate next year! @EMEUNET @RheumNow https://t.co/liWzYYbIxI

• https://x.com/DrMiniDey/status/2062843422172385751/photo/1